| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 24 | 2025 | 5097 | 2.130 |
Why?
|
| Sex Workers | 7 | 2014 | 116 | 1.820 |
Why?
|
| Pre-Exposure Prophylaxis | 7 | 2025 | 196 | 1.690 |
Why?
|
| Anti-HIV Agents | 9 | 2025 | 1324 | 1.540 |
Why?
|
| Female | 58 | 2025 | 9103 | 1.520 |
Why?
|
| Qualitative Research | 15 | 2025 | 321 | 1.490 |
Why?
|
| Humans | 76 | 2025 | 14537 | 1.490 |
Why?
|
| Sexual Behavior | 8 | 2020 | 320 | 1.430 |
Why?
|
| Health Personnel | 4 | 2022 | 231 | 1.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2025 | 262 | 1.280 |
Why?
|
| Attitude of Health Personnel | 3 | 2022 | 106 | 1.160 |
Why?
|
| Adult | 40 | 2024 | 5913 | 1.130 |
Why?
|
| Extreme Heat | 2 | 2024 | 3 | 1.110 |
Why?
|
| Anthropology, Medical | 3 | 2024 | 4 | 1.110 |
Why?
|
| Climate Change | 7 | 2024 | 27 | 1.050 |
Why?
|
| South Africa | 31 | 2025 | 7596 | 1.030 |
Why?
|
| Resilience, Psychological | 2 | 2017 | 11 | 1.010 |
Why?
|
| Health Services Accessibility | 5 | 2025 | 280 | 1.000 |
Why?
|
| Hygiene | 3 | 2015 | 23 | 0.960 |
Why?
|
| Interpersonal Relations | 4 | 2024 | 43 | 0.950 |
Why?
|
| Hope | 1 | 2024 | 4 | 0.950 |
Why?
|
| Focus Groups | 10 | 2024 | 196 | 0.920 |
Why?
|
| Violence | 4 | 2019 | 68 | 0.910 |
Why?
|
| Kangaroo-Mother Care Method | 1 | 2024 | 4 | 0.910 |
Why?
|
| Adolescent | 24 | 2025 | 2985 | 0.890 |
Why?
|
| Male | 32 | 2024 | 6754 | 0.840 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 115 | 0.820 |
Why?
|
| Snake Bites | 7 | 2017 | 9 | 0.810 |
Why?
|
| Medication Adherence | 4 | 2024 | 151 | 0.810 |
Why?
|
| Cities | 3 | 2022 | 37 | 0.760 |
Why?
|
| Women's Health | 3 | 2016 | 41 | 0.750 |
Why?
|
| Social Stigma | 3 | 2020 | 80 | 0.740 |
Why?
|
| Adolescent Health | 2 | 2019 | 15 | 0.740 |
Why?
|
| Interviews as Topic | 7 | 2025 | 203 | 0.740 |
Why?
|
| Blood Coagulation | 8 | 2019 | 29 | 0.730 |
Why?
|
| Young Adult | 18 | 2025 | 2498 | 0.700 |
Why?
|
| Pregnancy | 11 | 2024 | 1862 | 0.680 |
Why?
|
| Reproductive Health Services | 3 | 2018 | 66 | 0.680 |
Why?
|
| Postpartum Period | 4 | 2024 | 85 | 0.670 |
Why?
|
| Residence Characteristics | 2 | 2017 | 57 | 0.650 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2025 | 256 | 0.650 |
Why?
|
| Middle Aged | 25 | 2024 | 3601 | 0.640 |
Why?
|
| Prenatal Diagnosis | 1 | 2019 | 22 | 0.630 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 71 | 0.600 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 151 | 0.590 |
Why?
|
| Urban Population | 2 | 2017 | 257 | 0.590 |
Why?
|
| Kenya | 4 | 2024 | 183 | 0.580 |
Why?
|
| Tenofovir | 1 | 2018 | 171 | 0.580 |
Why?
|
| Social Environment | 1 | 2017 | 11 | 0.570 |
Why?
|
| Community Networks | 1 | 2017 | 13 | 0.570 |
Why?
|
| Refugees | 1 | 2017 | 10 | 0.570 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 26 | 0.570 |
Why?
|
| Mothers | 4 | 2024 | 195 | 0.560 |
Why?
|
| Transients and Migrants | 1 | 2017 | 39 | 0.550 |
Why?
|
| Factor V | 7 | 2014 | 10 | 0.550 |
Why?
|
| Health Services Needs and Demand | 2 | 2015 | 57 | 0.540 |
Why?
|
| Infant, Newborn | 8 | 2024 | 1479 | 0.530 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 411 | 0.530 |
Why?
|
| Antivenins | 5 | 2017 | 7 | 0.520 |
Why?
|
| Menstruation | 1 | 2015 | 10 | 0.510 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 187 | 0.500 |
Why?
|
| Leukocytes | 3 | 2023 | 14 | 0.500 |
Why?
|
| Urban Health | 1 | 2015 | 78 | 0.490 |
Why?
|
| Vagina | 3 | 2011 | 91 | 0.490 |
Why?
|
| Prenatal Care | 2 | 2016 | 147 | 0.480 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 43 | 0.480 |
Why?
|
| AIDS Serodiagnosis | 1 | 2014 | 44 | 0.470 |
Why?
|
| Critical Care | 1 | 2014 | 52 | 0.460 |
Why?
|
| Community Participation | 1 | 2014 | 42 | 0.450 |
Why?
|
| Snake Venoms | 4 | 2015 | 4 | 0.450 |
Why?
|
| Human Rights Abuses | 1 | 2013 | 2 | 0.440 |
Why?
|
| Hot Temperature | 3 | 2023 | 28 | 0.430 |
Why?
|
| Greenhouse Gases | 2 | 2024 | 4 | 0.430 |
Why?
|
| Social Support | 3 | 2020 | 77 | 0.430 |
Why?
|
| Child | 7 | 2024 | 2242 | 0.420 |
Why?
|
| Caregivers | 2 | 2024 | 76 | 0.420 |
Why?
|
| Russell's Viper | 3 | 2017 | 3 | 0.390 |
Why?
|
| Telomere | 4 | 2019 | 17 | 0.390 |
Why?
|
| Vaginal Douching | 1 | 2010 | 8 | 0.370 |
Why?
|
| Blood Coagulation Disorders | 3 | 2015 | 6 | 0.360 |
Why?
|
| Health Behavior | 1 | 2011 | 79 | 0.350 |
Why?
|
| Genitalia, Female | 1 | 2010 | 17 | 0.350 |
Why?
|
| Disclosure | 2 | 2020 | 25 | 0.340 |
Why?
|
| Perception | 2 | 2020 | 42 | 0.340 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 265 | 0.340 |
Why?
|
| Disseminated Intravascular Coagulation | 3 | 2017 | 14 | 0.330 |
Why?
|
| Sexuality | 1 | 2009 | 11 | 0.330 |
Why?
|
| Zimbabwe | 3 | 2020 | 120 | 0.320 |
Why?
|
| Global Health | 3 | 2021 | 193 | 0.300 |
Why?
|
| Blood Coagulation Factors | 4 | 2017 | 16 | 0.290 |
Why?
|
| Infant Health | 3 | 2022 | 16 | 0.290 |
Why?
|
| Health Education | 2 | 2020 | 35 | 0.290 |
Why?
|
| Plasma | 3 | 2017 | 39 | 0.280 |
Why?
|
| Aged, 80 and over | 9 | 2017 | 468 | 0.280 |
Why?
|
| Temperature | 2 | 2024 | 56 | 0.270 |
Why?
|
| Aged | 12 | 2019 | 1740 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2010 | 198 | 0.270 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 10 | 0.270 |
Why?
|
| Counseling | 5 | 2021 | 143 | 0.260 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 4 | 0.250 |
Why?
|
| Poverty | 2 | 2017 | 152 | 0.250 |
Why?
|
| Sex Factors | 2 | 2017 | 227 | 0.240 |
Why?
|
| Infant | 4 | 2024 | 2244 | 0.240 |
Why?
|
| Grandparents | 1 | 2024 | 6 | 0.240 |
Why?
|
| Parents | 1 | 2024 | 32 | 0.230 |
Why?
|
| Africa | 3 | 2014 | 376 | 0.230 |
Why?
|
| Blood Platelets | 4 | 2014 | 30 | 0.220 |
Why?
|
| Risk Factors | 7 | 2016 | 1475 | 0.220 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 9 | 0.220 |
Why?
|
| Tanzania | 2 | 2021 | 88 | 0.220 |
Why?
|
| Transgender Persons | 2 | 2013 | 24 | 0.210 |
Why?
|
| Microphthalmos | 1 | 2022 | 2 | 0.210 |
Why?
|
| Pregnant Women | 1 | 2023 | 89 | 0.210 |
Why?
|
| Breast Feeding | 1 | 2024 | 120 | 0.210 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2019 | 529 | 0.210 |
Why?
|
| Primary Health Care | 1 | 2025 | 240 | 0.210 |
Why?
|
| Animals | 9 | 2017 | 1081 | 0.200 |
Why?
|
| Child, Preschool | 3 | 2024 | 1748 | 0.200 |
Why?
|
| Partial Thromboplastin Time | 4 | 2015 | 13 | 0.200 |
Why?
|
| Africa, Eastern | 2 | 2023 | 17 | 0.200 |
Why?
|
| Colorectal Neoplasms | 3 | 2012 | 47 | 0.200 |
Why?
|
| Public Health | 2 | 2024 | 124 | 0.190 |
Why?
|
| Platelet Aggregation | 2 | 2019 | 12 | 0.190 |
Why?
|
| Condoms | 2 | 2013 | 88 | 0.190 |
Why?
|
| Disease Outbreaks | 2 | 2020 | 111 | 0.190 |
Why?
|
| Premature Birth | 1 | 2022 | 80 | 0.190 |
Why?
|
| Sexual Partners | 2 | 2020 | 215 | 0.190 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2014 | 103 | 0.190 |
Why?
|
| Gender-Based Violence | 1 | 2021 | 12 | 0.180 |
Why?
|
| Maternal Health | 1 | 2021 | 20 | 0.180 |
Why?
|
| Health Surveys | 2 | 2011 | 59 | 0.180 |
Why?
|
| Cell-Derived Microparticles | 2 | 2011 | 4 | 0.180 |
Why?
|
| Africa, Southern | 1 | 2020 | 91 | 0.180 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 11 | 0.180 |
Why?
|
| Thrombosis | 2 | 2011 | 47 | 0.170 |
Why?
|
| Culture | 2 | 2011 | 23 | 0.170 |
Why?
|
| Blotting, Southern | 1 | 2019 | 7 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2011 | 176 | 0.170 |
Why?
|
| Software | 1 | 2019 | 37 | 0.170 |
Why?
|
| Occupational Exposure | 1 | 2020 | 35 | 0.170 |
Why?
|
| Political Activism | 1 | 2019 | 3 | 0.170 |
Why?
|
| Platelet Function Tests | 1 | 2019 | 1 | 0.160 |
Why?
|
| Diarylheptanoids | 1 | 2019 | 1 | 0.160 |
Why?
|
| Curcumin | 1 | 2019 | 13 | 0.160 |
Why?
|
| Viper Venoms | 2 | 2017 | 7 | 0.160 |
Why?
|
| HIV | 2 | 2018 | 380 | 0.160 |
Why?
|
| Thymidylate Synthase | 2 | 2010 | 2 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.160 |
Why?
|
| Coitus | 1 | 2018 | 15 | 0.160 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2018 | 24 | 0.160 |
Why?
|
| Sexual Health | 1 | 2018 | 14 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.160 |
Why?
|
| Papillomavirus Vaccines | 1 | 2018 | 18 | 0.150 |
Why?
|
| School Health Services | 1 | 2018 | 19 | 0.150 |
Why?
|
| Water Microbiology | 1 | 2018 | 3 | 0.150 |
Why?
|
| Food Microbiology | 1 | 2018 | 4 | 0.150 |
Why?
|
| Community-Based Participatory Research | 1 | 2018 | 24 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2012 | 60 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 33 | 0.150 |
Why?
|
| Listeriosis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Health Services Research | 1 | 2018 | 58 | 0.150 |
Why?
|
| Africa South of the Sahara | 3 | 2018 | 353 | 0.150 |
Why?
|
| Immunization Programs | 1 | 2018 | 81 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.150 |
Why?
|
| Research Design | 1 | 2018 | 124 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 74 | 0.150 |
Why?
|
| Fear | 1 | 2017 | 11 | 0.140 |
Why?
|
| International Normalized Ratio | 5 | 2017 | 17 | 0.140 |
Why?
|
| Educational Status | 2 | 2023 | 68 | 0.140 |
Why?
|
| Environment | 1 | 2017 | 22 | 0.140 |
Why?
|
| Sex Offenses | 1 | 2017 | 29 | 0.140 |
Why?
|
| Safety | 1 | 2017 | 34 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 51 | 0.140 |
Why?
|
| Multiple Myeloma | 3 | 2006 | 12 | 0.140 |
Why?
|
| Drinking Behavior | 1 | 2016 | 2 | 0.140 |
Why?
|
| Maternal Death | 1 | 2016 | 25 | 0.140 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2016 | 9 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 656 | 0.140 |
Why?
|
| Maternal Mortality | 1 | 2016 | 58 | 0.130 |
Why?
|
| Prevalence | 2 | 2017 | 1192 | 0.130 |
Why?
|
| Heterozygote | 3 | 2011 | 43 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 55 | 0.130 |
Why?
|
| Deception | 1 | 2015 | 1 | 0.130 |
Why?
|
| Toxicity Tests | 1 | 2015 | 7 | 0.130 |
Why?
|
| Coagulants | 1 | 2015 | 10 | 0.130 |
Why?
|
| Shyness | 1 | 2015 | 1 | 0.130 |
Why?
|
| Feminine Hygiene Products | 1 | 2015 | 1 | 0.130 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 45 | 0.130 |
Why?
|
| Privacy | 1 | 2015 | 4 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 14 | 0.130 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 171 | 0.130 |
Why?
|
| Evaluation Studies as Topic | 1 | 2015 | 25 | 0.130 |
Why?
|
| Fluorouracil | 2 | 2012 | 19 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 112 | 0.120 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2019 | 472 | 0.120 |
Why?
|
| Informed Consent | 1 | 2014 | 8 | 0.120 |
Why?
|
| Confidentiality | 1 | 2014 | 13 | 0.120 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 1422 | 0.120 |
Why?
|
| Family | 1 | 2014 | 35 | 0.120 |
Why?
|
| Elapid Venoms | 1 | 2014 | 1 | 0.120 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2014 | 2 | 0.120 |
Why?
|
| Docosahexaenoic Acids | 1 | 2014 | 3 | 0.120 |
Why?
|
| Prothrombin | 1 | 2014 | 8 | 0.120 |
Why?
|
| Soccer | 1 | 2014 | 10 | 0.120 |
Why?
|
| Sex Work | 1 | 2014 | 39 | 0.110 |
Why?
|
| Laboratories | 1 | 2014 | 47 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2014 | 40 | 0.110 |
Why?
|
| Neutrophils | 2 | 2023 | 53 | 0.110 |
Why?
|
| Crotalid Venoms | 1 | 2013 | 1 | 0.110 |
Why?
|
| Viperidae | 1 | 2013 | 4 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2013 | 13 | 0.110 |
Why?
|
| Refusal to Treat | 1 | 2013 | 3 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2015 | 967 | 0.110 |
Why?
|
| Disease Transmission, Infectious | 1 | 2013 | 39 | 0.100 |
Why?
|
| Occupational Health | 1 | 2013 | 24 | 0.100 |
Why?
|
| Mass Screening | 1 | 2014 | 245 | 0.100 |
Why?
|
| Uganda | 1 | 2013 | 197 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 33 | 0.100 |
Why?
|
| Time Factors | 4 | 2017 | 507 | 0.100 |
Why?
|
| Unsafe Sex | 1 | 2012 | 46 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2017 | 1160 | 0.100 |
Why?
|
| Risk-Taking | 1 | 2012 | 121 | 0.100 |
Why?
|
| Glutathione Transferase | 3 | 2006 | 20 | 0.090 |
Why?
|
| Thrombin | 2 | 2014 | 8 | 0.090 |
Why?
|
| Self Medication | 1 | 2010 | 3 | 0.090 |
Why?
|
| Reproductive Medicine | 1 | 2010 | 4 | 0.090 |
Why?
|
| Condoms, Female | 1 | 2011 | 41 | 0.090 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2010 | 16 | 0.090 |
Why?
|
| Administration, Intravaginal | 1 | 2010 | 50 | 0.090 |
Why?
|
| Medicine, African Traditional | 1 | 2010 | 25 | 0.090 |
Why?
|
| Tandem Repeat Sequences | 1 | 2010 | 3 | 0.090 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2010 | 4 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 6 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 31 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 36 | 0.090 |
Why?
|
| Activated Protein C Resistance | 1 | 2009 | 1 | 0.090 |
Why?
|
| Thromboplastin | 1 | 2009 | 9 | 0.080 |
Why?
|
| Data Collection | 1 | 2010 | 86 | 0.080 |
Why?
|
| Social Control, Informal | 1 | 2009 | 5 | 0.080 |
Why?
|
| Prothrombin Time | 3 | 2015 | 15 | 0.080 |
Why?
|
| Telomerase | 1 | 2008 | 1 | 0.080 |
Why?
|
| Melanoma | 1 | 2008 | 9 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2008 | 19 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 563 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 12 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 77 | 0.080 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 99 | 0.080 |
Why?
|
| Mental Health | 2 | 2020 | 91 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2009 | 225 | 0.080 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2007 | 5 | 0.070 |
Why?
|
| Lipoproteins | 1 | 2007 | 13 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 14 | 0.070 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 18 | 0.070 |
Why?
|
| Minisatellite Repeats | 1 | 2007 | 3 | 0.070 |
Why?
|
| Case-Control Studies | 5 | 2009 | 480 | 0.070 |
Why?
|
| Epoxide Hydrolases | 1 | 2006 | 1 | 0.070 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2006 | 2 | 0.070 |
Why?
|
| Thrombophilia | 1 | 2006 | 2 | 0.070 |
Why?
|
| Protein C | 1 | 2006 | 4 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2006 | 10 | 0.060 |
Why?
|
| Sri Lanka | 2 | 2017 | 4 | 0.060 |
Why?
|
| Health Policy | 2 | 2019 | 140 | 0.060 |
Why?
|
| Drug Implants | 1 | 2024 | 24 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2004 | 1 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 6 | 0.060 |
Why?
|
| Hemorrhage | 2 | 2017 | 72 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2025 | 127 | 0.060 |
Why?
|
| Anthropology, Cultural | 1 | 2024 | 5 | 0.060 |
Why?
|
| Burkina Faso | 1 | 2024 | 29 | 0.060 |
Why?
|
| Greenhouse Effect | 1 | 2024 | 2 | 0.060 |
Why?
|
| Hazardous Substances | 1 | 2024 | 3 | 0.060 |
Why?
|
| Granulocytes | 1 | 2023 | 1 | 0.060 |
Why?
|
| Safe Sex | 2 | 2014 | 68 | 0.050 |
Why?
|
| World Health Organization | 1 | 2024 | 137 | 0.050 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2003 | 1 | 0.050 |
Why?
|
| Lymphoma, Follicular | 1 | 2003 | 2 | 0.050 |
Why?
|
| Snakes | 2 | 2015 | 2 | 0.050 |
Why?
|
| Financial Statements | 1 | 2022 | 2 | 0.050 |
Why?
|
| Algorithms | 1 | 2023 | 106 | 0.050 |
Why?
|
| Peer Group | 1 | 2022 | 14 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2002 | 1 | 0.050 |
Why?
|
| Leukapheresis | 1 | 2002 | 1 | 0.050 |
Why?
|
| Blood Cells | 1 | 2002 | 4 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 12 | 0.050 |
Why?
|
| Biodiversity | 1 | 2022 | 11 | 0.050 |
Why?
|
| Placenta | 1 | 2022 | 44 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2017 | 889 | 0.050 |
Why?
|
| Australia | 2 | 2013 | 48 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 385 | 0.050 |
Why?
|
| Microscopy | 1 | 2021 | 21 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2021 | 24 | 0.050 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 30 | 0.050 |
Why?
|
| Narration | 1 | 2020 | 10 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 101 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 16 | 0.040 |
Why?
|
| New South Wales | 2 | 2010 | 4 | 0.040 |
Why?
|
| Biomarkers | 2 | 2013 | 327 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 31 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2020 | 56 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 71 | 0.040 |
Why?
|
| Phenotype | 2 | 2010 | 158 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 56 | 0.040 |
Why?
|
| Public Policy | 1 | 2019 | 24 | 0.040 |
Why?
|
| Aggression | 1 | 2019 | 13 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 2 | 2014 | 551 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 188 | 0.040 |
Why?
|
| Weather | 1 | 2018 | 7 | 0.040 |
Why?
|
| Foodborne Diseases | 1 | 2018 | 6 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 40 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 89 | 0.040 |
Why?
|
| Health Resources | 1 | 2018 | 66 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2018 | 62 | 0.040 |
Why?
|
| Alcohol Abstinence | 1 | 2016 | 2 | 0.030 |
Why?
|
| Maternal Health Services | 1 | 2016 | 52 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 80 | 0.030 |
Why?
|
| Cats | 1 | 2015 | 3 | 0.030 |
Why?
|
| Social Class | 1 | 2016 | 73 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 11 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 2015 | 11 | 0.030 |
Why?
|
| Rabbits | 1 | 2015 | 35 | 0.030 |
Why?
|
| Cattle | 1 | 2015 | 28 | 0.030 |
Why?
|
| Swine | 1 | 2015 | 49 | 0.030 |
Why?
|
| Rats | 1 | 2015 | 130 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2015 | 24 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 125 | 0.030 |
Why?
|
| Genotype | 2 | 2010 | 442 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 21 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2014 | 4 | 0.030 |
Why?
|
| Human Trafficking | 1 | 2014 | 2 | 0.030 |
Why?
|
| Financing, Government | 1 | 2014 | 11 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 472 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2013 | 10 | 0.030 |
Why?
|
| Aryldialkylphosphatase | 2 | 2004 | 3 | 0.030 |
Why?
|
| Xenobiotics | 2 | 2004 | 4 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 25 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 22 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2014 | 272 | 0.030 |
Why?
|
| Arylamine N-Acetyltransferase | 2 | 2004 | 10 | 0.030 |
Why?
|
| Length of Stay | 1 | 2013 | 43 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2013 | 27 | 0.030 |
Why?
|
| Public Health Administration | 1 | 2013 | 14 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 42 | 0.030 |
Why?
|
| Leucovorin | 1 | 2012 | 11 | 0.030 |
Why?
|
| Factor VIII | 1 | 2013 | 54 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2014 | 321 | 0.030 |
Why?
|
| Cell Count | 1 | 2011 | 10 | 0.020 |
Why?
|
| Pregnancy, Unwanted | 1 | 2011 | 9 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 31 | 0.020 |
Why?
|
| Gender Identity | 1 | 2011 | 23 | 0.020 |
Why?
|
| Venoms | 1 | 2010 | 2 | 0.020 |
Why?
|
| Decision Making | 1 | 2011 | 53 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 1 | 0.020 |
Why?
|
| Deoxyuridine | 1 | 2010 | 1 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2010 | 1 | 0.020 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2010 | 1 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 15 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2010 | 12 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 29 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 64 | 0.020 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2009 | 1 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2009 | 3 | 0.020 |
Why?
|
| E-Selectin | 1 | 2009 | 14 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2009 | 23 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 67 | 0.020 |
Why?
|
| Hemostatics | 1 | 2009 | 17 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 150 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2008 | 1 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2008 | 3 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 3 | 0.020 |
Why?
|
| Diamines | 1 | 2008 | 2 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2008 | 3 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2008 | 4 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2008 | 7 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 20 | 0.020 |
Why?
|
| Quinolines | 1 | 2008 | 14 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 32 | 0.020 |
Why?
|
| Mutation | 1 | 2009 | 306 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 149 | 0.020 |
Why?
|
| Benzene | 1 | 2006 | 2 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 263 | 0.020 |
Why?
|
| Alleles | 1 | 2007 | 143 | 0.020 |
Why?
|
| Thrombin Time | 1 | 2006 | 2 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 10 | 0.020 |
Why?
|
| Peptides | 1 | 2006 | 40 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2004 | 11 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 54 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2004 | 12 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2004 | 25 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 13 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2002 | 1 | 0.010 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2002 | 1 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 5 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Peptide Initiation Factors | 1 | 2002 | 2 | 0.010 |
Why?
|
| Esterases | 1 | 2002 | 4 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 199 | 0.010 |
Why?
|